Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Autoimmune Liver Disease
How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?
Related Questions
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
What is your approach to treatment of immune-mediated overlap syndromes, such as AIH-PBC?
What patient factors guide your selection of maintenance therapies for a patient with auto-immune hepatitis?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
What is your approach to the management of anti-pruritic therapies in patients with cholestatic liver disease?
How would you approach a referral for concern for hemochromatosis with ferritin elevation but otherwise normal iron studies?
All things being equal, what patient factors are you looking at in the selection of TAF or TDF in the management of hepatitis B?
When do you pursue liver biopsy for assessment of DILI?
In what scenario do you continue surveillance of benign liver tumors, e.g., hepatocellular adenoma, in pregnant patients?
Who would be the right candidate in which TIPS placement would reduce portal hypertension to allow for a previously unattainable procedure?
